This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 118.75% and 90.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Affimed (AFMD) This Earnings Season?
by Zacks Equity Research
Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.
Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for Affimed (AFMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
What Makes Affirmed Therapeutics (AFMD) a New Strong Buy Stock
by Zacks Equity Research
Affirmed Therapeutics (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Affirmed Therapeutics (AFMD) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Affimed (AFMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Implied Volatility Surging for Affimed (AFMD) Stock Options
by Zacks Equity Research
Affimed (AFMD) needs investors to pay close attention to the stock based on moves in the options market lately.
Affirmed Therapeutics (AFMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of -29.41% and 18.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
by Zacks Equity Research
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
Rockwell Automation (ROK) Q4 Earnings: A Beat in the Offing?
by Zacks Equity Research
Rockwell Automation's (ROK) Q4 performance will be supported by accelerated investments and higher backlogs despite weakness in Transportation vertical and tariff woes.
Tenet Healthcare (THC) Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) third quarter earnings is likely to gain from solid performance by the Conifer Segment
Affirmed Therapeutics (AFMD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Affirmed Therapeutics (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare's (MOH) Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to perform well in the third quarter on the back of a solid Medicaid business and its operational excellence.
Company News For Oct 10, 2018
by Zacks Equity Research
Companies in the news are: PZZA, MSFT, AFMD and SBUX
Affimed Down After Clinical Hold on Two Early-Stage Studies
by Zacks Equity Research
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
Implied Volatility Surging for Affimed (AFMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)
by Zacks Equity Research
Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.
Affimed (AFMD) Soars: Stock Adds 10.8% in Session
by Zacks Equity Research
Affimed (AFMD) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.
Affimed (AFMD) Surges On Collaboration Contract With Roche
by Zacks Equity Research
Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.
Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 5.88% and -70.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Affimed (AFMD) Stock Options
by Zacks Equity Research
Affimed (AFMD) needs investors to pay close attention to the stock based on moves in the options market lately.
Why Earnings Season Could Be Great for Affimed (AFMD)
by Zacks Equity Research
Affimed (AFMD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Affimed (AFMD) Looks Good: Stock Moves Up 8.7% in Session
by Zacks Equity Research
Affimed N.V. (AFMD) moved big last session, as the company saw its shares rise over 8% on the day.